Instrumental analysis of finger tapping reveals a novel early biomarker of parkinsonism in idiopathic rapid eye movement sleep behaviour disorder

Krupička, Radim; Krýže, Petr; Neťuková, Slávka; Duspivová, Tereza; Klempíř, Ondřej; Szabó, Zoltán; Dušek, Petr; Šonka, Karel; Rusz, Ján; Růžička, Evžen

doi:10.1016/j.sleep.2020.07.019

Cited by 14 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Poor spontaneous rhythm timing and perception has also been shown: performance in a small cohort of patients with isolated RBD was similar to that in individuals with mild Parkinson's disease, 20 whereas, in another cohort of patients with isolated RBD, finger tapping amplitude and velocity decrement were impaired when compared with controls, suggesting prodromal bradykinesia. 19 Finally, increased error rates for anti saccadic but not prosaccadic eye movements have been reported in patients with isolated RBD compared with controls. 17 Despite the precision offered by these approaches, there is also a recognised need to quickly and accurately assess motor function in the clinic and home environments.…”

Section: Motor Functionmentioning

confidence: 96%

“…Several cross-sectional studies using instrumental assessments have highlighted the use of gait, 14,15 speech, 16 saccadic eye movements, 17 rhythm, 18 and finger tapping, 19 with sensitivity and specificity of up to 80%, to identify the presence of isolated RBD. For example, changes in home-based spontaneous walking tasks and decreased gait speed, cadence, and step variability have been reported in patients with isolated RBD, compared with age-matched controls.…”

Section: Motor Functionmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Miglis

Adler

Antelmi

et al. 2021

The Lancet Neurology

Self Cite

127

120

View full text Add to dashboard Cite

Section: Motor Functionmentioning

confidence: 96%

Section: Motor Functionmentioning

confidence: 99%

Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Miglis

Adler

Antelmi

et al. 2021

The Lancet Neurology

Self Cite

127

120

View full text Add to dashboard Cite

“…More recently assessment of motor function with wearable devices or computer detection algorithms was used in several studies, allowing an objective evaluation of gait, 36 balance, 37 eye movements, 38 and bradykinesia. 39 …”

Section: Rem Sleep Behavior Disorder and Biomarkers For Phenoconversi...mentioning

confidence: 99%

Considering REM Sleep Behavior Disorder in the Management of Parkinson’s Disease

Figorilli¹,

Meloni²,

Lanza³

et al. 2023

NSS

View full text Add to dashboard Cite

Rapid eye movement (REM) sleep behavior disorder (RBD) is the result of the loss of physiological inhibition of muscle tone during REM sleep, characterized by dream-enacting behavior and widely recognized as a prodromal manifestation of alpha-synucleinopathies. Indeed, patients with isolated RBD (iRBD) have an extremely high estimated risk to develop a neurodegenerative disease after a long follow up. Nevertheless, in comparison with PD patients without RBD (PDnoRBD), the occurrence of RBD in the context of PD (PDRBD) seems to identify a unique, more malignant phenotype, characterized by a more severe burden of disease in terms of both motor and non-motor symptoms and increased risk for cognitive decline. However, while some medications (eg, melatonin, clonazepam, etc.) and non-pharmacological options have been found to have some therapeutic benefits on RBD there is no available treatment able to modify the disease course or, at least, slow down the neurodegenerative process underlying phenoconversion. In this scenario, the long prodromal phase may allow an early therapeutic window and, therefore, the identification of multimodal biomarkers of disease onset and progression is becoming increasingly crucial. To date, several clinical (motor, cognitive, olfactory, visual, and autonomic features) neurophysiological, neuroimaging, biological (biofluids or tissue biopsy), and genetic biomarkers have been identified and proposed, also in combination, as possible diagnostic or prognostic markers, along with a potential role for some of them as outcome measures and index of treatment response. In this review, we provide an insight into the present knowledge on both existing and future biomarkers of iRBD and highlight the difference with PDRBD and PDnoRBD, including currently available treatment options.

show abstract

“…7 Parkinsonian bradykinetic behaviors have also been detected in iRBD using high-precision, quantitative methods. Instrumented analyses of index and thumb tapping have revealed decreased movement speed 19 and a sequence effect 22 in people with a short duration of iRBD symptoms (~5 years), suggesting early parkinsonian bradykinesia in people with iRBD. However, there are no longitudinal studies utilizing instrumented measures of bradykinesia in iRBD.…”

Section: Limb Bradykinesiamentioning

confidence: 99%

Motor Dysfunction in REM Sleep Behavior Disorder: A Rehabilitation Framework for Prodromal Synucleinopathy

Summers

Rafferty

Howell

et al. 2021

Neurorehabil Neural Repair

View full text Add to dashboard Cite

Parkinson disease (PD) and other related diseases with α-synuclein pathology are associated with a long prodromal or preclinical stage of disease. Predictive models based on diagnosis of idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) make it possible to identify people in the prodromal stage of synucleinopathy who have a high probability of future disease and provide an opportunity to implement neuroprotective therapies. However, rehabilitation providers may be unaware of iRBD and the motor abnormalities that indicate early motor system dysfunction related to α-synuclein pathology. Furthermore, there is no existing rehabilitation framework to guide early interventions for people with iRBD. The purpose of this work is to (1) review extrapyramidal signs of motor system dysfunction in people with iRBD and (2) propose a framework for early protective or preventive therapies in prodromal synucleinopathy using iRBD as a predictive marker. Longitudinal and cross-sectional studies indicate that the earliest emerging motor deficits in iRBD are bradykinesia, deficits performing activities of daily living, and abnormalities in speech, gait, and posture. These deficits may emerge up to 12 years before a diagnosis of synucleinopathy. The proposed rehabilitation framework for iRBD includes early exercise-based interventions of aerobic exercise, progressive resistance training, and multimodal exercise with rehabilitation consultations to address exercise prescription, progression, and monitoring. This rehabilitation framework may be used to implement neuroprotective, multidisciplinary, and proactive clinical care in people with a high likelihood of conversion to PD, dementia with Lewy bodies, or multiple systems atrophy.

show abstract

Instrumental analysis of finger tapping reveals a novel early biomarker of parkinsonism in idiopathic rapid eye movement sleep behaviour disorder

Cited by 14 publications

References 28 publications

Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Considering REM Sleep Behavior Disorder in the Management of Parkinson’s Disease

Motor Dysfunction in REM Sleep Behavior Disorder: A Rehabilitation Framework for Prodromal Synucleinopathy

Contact Info

Product

Resources

About